Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (S)-Verapamil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 3/20 | 1.00 |
| ▸ | CACNA1F known ✓ | O60840 | 2/20 | 1.00 |
| ▸ | CACNA1D known ✓ | Q01668 | 2/20 | 1.00 |
| ▸ | CACNA1S known ✓ | Q13698 | 2/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 9/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 8/20 | 1.00 |
| ▸ | ABCC1 | P33527 | 4/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Verapamil SCHEMBL29450374 | 1.00 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| (S)-Verapamil SCHEMBL29768846 | 1.00 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| Dexverapamil SCHEMBL30402443 | 1.00 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| Verapamil SCHEMBL29450364 | 1.00 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| Verapamil SCHEMBL29064783 | 1.00 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| Verapamil SCHEMBL16742 | 1.00 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| Dexverapamil SCHEMBL33297 | 1.00 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| Dexverapamil SCHEMBL29423253 | 1.00 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| Verapamil SCHEMBL1902363 | 1.00 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| Verapamil SCHEMBL29440902 | 1.00 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4314018-A1 | METHODS AND COMPOSITIONS FOR HIGH-POTENCY POLYPEPTIDE-BASED PROTEIN INHIBITION | Baylor College of Medicine (US) | 2024-02-07 | — | — | EP | claimed |
| US-20230355711-A1 | VIMENTIN AND FRAGMENTS OR DERIVATIVES THEREOF FOR CORONAVIRUS TREATMENT AND PREVENTION | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2023-11-09 | — | — | US | claimed |
| US-20230210902-A1 | SARS-COV-2-SPECIFIC T CELLS | NATIONAL INSTITUTES OF HEALTH | 2023-07-06 | — | — | US | claimed |
| EP-4149496-A1 | SARS-COV-2-SPECIFIC T CELLS | Board of Regents, The University of Texas System (US) | 2023-03-22 | — | — | EP | claimed |
| US-20220401553-A1 | PARAPOXVIRUS FOR CONDITIONING FOR AND TREATMENT OF CORONAVIRUS INFECTIONS | AICURIS GMBH & CO. KG (DE) | 2022-12-22 | — | — | US | claimed |
| WO-2022213076-A1 | METHODS AND COMPOSITIONS FOR HIGH-POTENCY POLYPEPTIDE-BASED PROTEIN INHIBITION | BAYLOR COLLEGE OF MEDICINE (US) | 2022-10-06 | — | — | WO | claimed |
| EP-3906970-B1 | PARAPOXVIRUS FOR CONDITIONING AND TREATMENT OF CORONAVIRUS INFECTIONS | AICURIS GMBH & CO KG (DE) | 2022-07-06 | — | — | EP | claimed |
| US-20220193204-A1 | USES OF A2 DOMAIN OF VON WILLEBRAND FACTOR | BAYLOR COLLEGE OF MEDICINE (US) | 2022-06-23 | — | — | US | claimed |
| EP-3969036-A1 | USES OF A2 DOMAIN OF VON WILLEBRAND FACTOR | Baylor College of Medicine (US) | 2022-03-23 | — | — | EP | claimed |
| US-20150209308-A1 | METHODS TO INHIBIT INTRACELLULAR GROWTH OF BACTERIA AND TO TREAT BACTERIA-MEDIATED DISEASES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH | 2015-07-30 | — | — | US | claimed |
| US-9078873-B2 | Compositions and methods for preventing cardiac arrhythmia | CORMATRIX CARDIOVASCULAR, INC. (US) | 2015-07-14 | — | — | US | claimed |
| US-20150150913-A1 | Compositions and Methods for Preventing Cardiac Arrhythmia | CORVIVO CARDIOVASCULAR, INC. | 2015-06-04 | — | — | US | claimed |
| WO-2014039011-A1 | METHODS TO INHIBIT INTRACELLULAR GROWTH OF BACTERIA AND TO TREAT BACTERIA-MEDIATED DISEASES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-03-13 | — | — | WO | claimed |
| US-12606631-B2 | Antibodies which bind human endothelin receptor a (ETAR) | REMD BIOTHERAPEUTICS INC (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4714452-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | Gilead Sciences, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20250149121-A1 | DETECTION OF PEPTIDE STRUCTURES FOR DIAGNOSING AND TREATING SEPSIS AND COVID | VENN BIOSCIENCES CORPORATION | 2025-05-08 | — | — | US | disclosed |
| US-20150073535-A1 | Treatment of coronary artery lesions with a scaffold having vessel scaffold interactions that reduce or prevent angina | ABBOTT CARDIOVASCULAR SYSTEMS INC. | 2015-03-12 | — | — | US | disclosed |
| WO-2014039011-A1 | METHODS TO INHIBIT INTRACELLULAR GROWTH OF BACTERIA AND TO TREAT BACTERIA-MEDIATED DISEASES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-03-13 | — | — | WO | disclosed |
| US-20130101666-A1 | LIPOSOME INCLUDING ELASTIN-LIKE POLYPEPTIDE CONJUGATED TO MOIETY CONTAINING HYDROPHOBIC GROUP, CHEMOSENSITIZER AND ANTICANCER AGENT AND USE THEREOF | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2013-04-25 | — | — | US | disclosed |
| EP-2583690-A1 | Liposome including elastin-like polypeptide hydrophobic group conjugate, chemosensitizer and anticancer agent and use thereof | Samsung Electronics Co., Ltd (KR) | 2013-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606631-B2 | Antibodies which bind human endothelin receptor a (ETAR) | EDNRA, EDNRB, FCGR2A | CACNA1C 1226/4885CACNA1F 1118/4885CACNA1D 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.